The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Prognostic Factor Studies
Abstract
The treatment of cancer has changed over the past centuries, moving away from the administration of broadly acting cytotoxic drugs toward the use of more specific therapies (van’t Veer and Bernards [ 33 ]). There is a shift from a “one-size” or “one- dose-fits-all” approach to a more personalized medicine. The idea behind this is to give the right dose of the right drug for the right indication for the right patient in the right time. Hamburg and Collins [ 12 ] called this approach a path to personalized medicine and described the need for the Food and Drug Administration (FDA) and National Institutes of Health (NIH) to support its growth. They gave three examples of FDA-approved drugs and diagnostics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
The adaptive lasso and its oracle properties
Zou, H. (2006) · Journal of the American Statistical Association · doi:10.1198/016214506000000735 · Cited by 7,470
Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures
Steyerberg, E. W., Vickers, A. J., Cook, N. R., Gerds, T., Gonen, M., Obuchowski, N., Pencina, M. J., & Kattan, M. W. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181c30fb2 · Cited by 5,170
Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression
Vittinghoff, E., & McCulloch, C. E. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk052 · Cited by 4,359
Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author)
Breiman, L. (2001) · Statistical Science · doi:10.1214/ss/1009213726 · Cited by 4,340
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Estimating the error rate of a prediction rule: improvement on cross-validation
Efron, B. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10477973 · Cited by 2,300
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Self-citationPeduzzi, P., Concato, J., Feinstein, A. R., & Holford, T. R. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00048-8 · Cited by 2,154
Steyerberg, E. W. (2009) · Statistics for Biology and Health · doi:10.1007/978-0-387-77244-8 · Cited by 1,491
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Self-citationSubgroup analysis in randomised controlled trials: importance, indications, and interpretation
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17709-5 · Cited by 942
Application of artificial neural networks to clinical medicine
Baxt, W. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91804-3 · Cited by 677
Introduction to neural networks
Cross, S. S., Harrison, R. F., & Kennedy, R. L. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91746-2 · Cited by 615
A new measure of prognostic separation in survival data
Royston, P., & Sauerbrei, W. (2004) · Statistics in Medicine · doi:10.1002/sim.1621 · Cited by 450
Self-citationReview of survival analyses published in cancer journals
Altman, D., De Stavola, B., Love, S., & Stepniewska, K. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.364 · Cited by 438
Methodological challenges in the evaluation of prognostic factors in breast cancer.
Altman, D. G., & Lyman, G. H. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006193704132 · Cited by 271
Mallett, S., Timmer, A., Sauerbrei, W., & Altman, D. G. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605462 · Cited by 122
Self-citation
Cited by
Unbiased Recursive Partitioning: A Conditional Inference Framework
Hothorn, T., Hornik, K., & Zeileis, A. (2006) · Journal of Computational and Graphical Statistics · doi:10.1198/106186006x133933 · Cited by 4,021
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Self-citationVariable selection – A review and recommendations for the practicing statistician
Heinze, G., Wallisch, C., & Dunkler, D. (2018) · Biometrical Journal · doi:10.1002/bimj.201700067 · Cited by 1,639
Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research
Steyerberg, E. W., Moons, K. G. M., van der Windt, D. A., Hayden, J. A., Perel, P., Schroter, S., Riley, R. D., Hemingway, H., Altman, D. G., & for the PROGRESS Group (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001381 · Cited by 1,508
REporting recommendations for tumour MARKer prognostic studies (REMARK).
for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394
Self-citation
Metadata
- Authors
- Schumacher, M., Holländer, N., Schwarzer, G., Binder, H., & Sauerbrei, W.
- Venue
- Handbook of Statistics in Clinical Oncology, Third Edition
- Publisher
- Chapman and Hall/CRC
- Published
- 2012-03-16
- Pages
- 415-470
- OpenAlex
- W2496544297
- Cited by
- 56
- References
- 19
- FWCI
- 15.96
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.